A Three-part Single-center, Phase 1 Study to Assess the Tolerability, Safety, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of Ascending Single and Multiple Doses of AC-084 in Healthy Subjects and to Investigate the Pharmacokinetics of a Single Dose of AC-084 in Healthy CYP2C9 Poor Metabolizers
Phase of Trial: Phase I
Latest Information Update: 13 Apr 2018
At a glance
- Drugs AC 084 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
- Sponsors Actelion Pharmaceuticals
- 10 Apr 2018 Status changed from recruiting to discontinued.
- 06 Jul 2017 Planned End Date changed from 31 Dec 2017 to 20 Dec 2017.
- 06 Jul 2017 Planned primary completion date changed from 31 Dec 2017 to 20 Dec 2017.